Could a new pill curb alcohol cravings? early trial tests GET73
NCT ID NCT04831684
First seen Jan 29, 2026 · Last updated Jun 19, 2026 · Updated 22 times
Summary
This study tested a drug called GET73 in 79 people with alcohol use disorder who were not seeking treatment. Participants took GET73 or a placebo for 8 days and had MRI scans to see how their brains reacted to alcohol cues. The goal was to see if GET73 could reduce drinking and change brain chemistry related to alcohol cravings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charleston Alcohol Research Center, Institute of Psychiatry, Medical University of South Carolina
Charleston, South Carolina, 29425, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GET73
What this could lead to
If it works, this could point toward a new medication to help people with alcohol use disorder drink less or control their cravings.
What could go wrong
This was a small, early-phase trial (Phase 1/2) with only 79 participants and short-term dosing (8 days). The results may not apply to everyone, and the drug may not work as hoped in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.